REG - ReNeuron Group plc - PDMR Interest in Shares and Share Options <Origin Href="QuoteRef">RQE.L</Origin> - Part 1

ReNeuronAnnouncement

11/10/2017 13:35

RNS Number : 3426T
ReNeuron Group plc
11 October 2017
11 October 2017
AIM: RENE
ReNeuron Group plc
Director/PDMR Interest in Shares and Share Options 
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that, on 9 October 2017, the following grants made on 11 September 2017 under the Company's Long Term Incentive Plan (LTIP) were deemed accepted by the relevant Persons Discharging Managerial Responsibilities (PDMRs). Share option grants made to Directors on 11 September 2017, which were separately announced by RNS on 12 September 2017, were also deemed accepted by those Directors on 9 October 2017. Under the terms of the grants, 9 October 2017 was the final day by which grantees could decline the option granted to them on 11 September 2017.
Name
Title
Date of grant of LTIP share options
Date LTIP share options accepted
Number of LTIP share options granted & accepted
Total shares over which options are held
Percentage of issued shares under option
Randolph Corteling 
Head of Research
11 Sept 17
9 Oct 17
 3,000,000
12,604,041
0.40%
Sharon Grimster
VP Development & General Manager - Wales
11 Sept 17
9 Oct 17
5,750,000
19,658,334
0.62% 
John Hawkins (i)
Financial Controller
11 Sept 17
9 Oct 17
 400,000
 1,600,000
0.05% 
Julian Howell
Chief Medical Officer
11 Sept 17
9 Oct 17
 5,566,667
21,474,243
0.68% 
Shaun Stapleton
Head of Regulatory Affairs
11 Sept 17
9 Oct 17
 4,533,333
17,461,363
0.55% 
John Sinden
Chief Scientific Officer
11 Sept 17
9 Oct 17
2,983,333
21,599,743
0.68% 
The LTIP awards are share options granted at nominal value and are subject to a three-year holding period, exercisable from the third anniversary of the award. The options are exercisable subject to the achievement of the following performance conditions:
1) When the first patientisadministered with a ReNeuron cell therapy in an eighth clinical trial, one third of the options will vest. 
2) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
3) If the Total Shareholder Return (TSR) of the Companymeets or exceeds that of the FTSE AIM Healthcare Indexin any given three year period from the date of grant, one third of the options will vest. 
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
(i) The grant to Mr Hawkins was made under the Company's Employee Share Option Plan and is exercisable subject to achievement of performance conditions (1) and (2) above, with 50% of the options vesting in each case.
ENDS
ENQUIRIES:
ReNeuron
+44 (0)20 3819 8400
Olav Helleb , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson



Stifel Nicolaus Europe Limited
+44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

Nplus1 Singer Advisory LLP
+44 (0) 20 7496 3000
Mark Taylor (Joint Broker)

About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa. 
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Randolph Corteling
2
Reason for the notification
a)
Position/status
Head of Research
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
3,000,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
(Disclosure in relation to share options granted and accepted by Directors and PDMRs) 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Sharon Grimster
2
Reason for the notification
a)
Position/status
VP Development & General Manager - Wales 
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
5,750,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
John Hawkins
2
Reason for the notification
a)
Position/status
Financial Controller
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
400,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Julian Howell
2
Reason for the notification
a)
Position/status
Chief Medical Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
5,566,667
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Shaun Stapleton
2
Reason for the notification
a)
Position/status
Head of Regulatory Affairs
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
4,533,333
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
John Sinden
2
Reason for the notification
a)
Position/status
Chief Scientific Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
2,983,333
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Olav Hellebo
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
9,766,667
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Michael Hunt
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
6,800,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
John Berriman
2
Reason for the notification
a)
Position/status
Non-Executive Chairman
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
500,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Simon Cartmell
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
500,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Tim Corn
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
500,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Claudia D'Augusta
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
500,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Chris Evans
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
500,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mike Owen
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ReNeuron Group plc
b)
LEI
N/A
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares 1p
RENE - GB00B0DZML60
b)
Nature of the transaction
Grant of share options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1p
500,000
d)
Aggregated information
N/A
e)
Date of the transaction
Granted 11 September 2017; Deemed accepted 9 October 2017
f)
Place of the transaction
Outside a trading venue
 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHEAAEFFAPXFFF